T4 concentrations due to increased excretion of T4-glucuronide (Rickenbacher et al, 1986; Brouwer and Van den Berg, 1986; Darnerud etal., 1996) . However, this mechanism may be unlikely in humans because competitive binding has not been shown for thyroxine-binding globulin, the human T4-transport protein (Lans et al, 1994) . It has also been shown that PCBs (Barter and Klaassen, 1994) and chlorinated benzenes (Van Raaij et al, 1993) increase glucuronidation and biliary excretion of T4. The structural similarities between PCBs and thyroid hormones also suggest that PCBs may bind to hormone receptor sites at the target tissue, which would lead to hypo-or hyperthyroid effects depending upon the response of the target tissue to the inappropriate ligand (blocked vs stimulated receptor, respectively). In addition, there is some evidence that PCBs may directly damage the thyroid gland (Collins and Capen, 1980; Ness et al., 1993) . Therefore, the functional effects of PCBs on developing organ systems (for review, see Brouwer et al., 1995) , such as the nervous system, may be indirect manifestations of altered thyroid hormone homeostasis (Porterfield, 1994) .
Hypothyroidism occurring during nervous system development can have permanent and disastrous consequences. For example, dietary iodine deficiency during human pregnancy causes hypothyroidism which results in mental retardation of the offspring (i.e., endemic cretinism; Boyages and Halpern, 1993) . Neurological cretins are often deaf and typically demonstrate delays in motor development. Whereas the auditory system of humans is fully functional by birth, the auditory system in rats develops during the first 2-3 weeks after birth (Rubel, 1978) . Rats and mice made hypothyroid with a goitrogen during this early postnatal period demonstrate profound and permanent morphological (Deol, 1973 (Deol, , 1976 Uziel et al., 1981 Uziel et al., , 1985a and functional (Uziel etal., 1980 (Uziel etal., , 1985b Goldey et al, 1995b; Meza et al, 1996) auditory damage, indicating that the first few postnatal weeks defines a sensitive period (Eggermont, 1986) in auditory development in rats (Hebert et al., 1985; Uziel, 1986) . We previously reported that the severity of the functional auditory damage is proportional to the degree of thyroid hormone depletion (Goldey et al, 1995b) , and it has also been shown that T4 administered at welldefined, chronological intervals will spare particular regions of the cochlea from damage by goitrogen-induced hypothyroidism (Deol, 1973; Uziel et al, 1985a, b) . Such experimental findings in rats and mice, as well as clinical findings in cretins, indicate that the auditory system may be a target for the thyrotoxic effects of polychlorinated biphenyls.
Previously, we reported that developmental exposure to Aroclor 1254 reduced circulating thyroid hormone concentrations, accelerated the age of eye opening, reduced pup body weights, delayed motor activity development, reduced weanling startle amplitudes, and caused low-frequency hearing loss (Goldey et al, 1995a) . We hypothesized that PCB-induced hypothyroxinemia may have caused some of these effects. In the present study, we tested this hypothesis by investigating whether T4 replacement therapy would attenuate or eliminate any of the reported effects. The current findings indicate that hormone therapy partially attenuated the effects of Aroclor 1254 (A 1254) on auditory and motor function, while it exacerbated the effects on the age of eye opening.
METHODS

Animals
Eighty primiparous Long-Evans rats arrived from Charles River Laboratory (Raleigh, NC) on gestation day (GD) 2 (the day of insemination was GD 0). Rats were housed individually, in standard plastic hanging cages (45 X 24 X 20 cm) with sterilized pine shavings as bedding, in an AAALAC-approved animal facility. All experiments were approved in advance by the National Health and Environmental Effects Research Laboratory animal care committee of the U.S. Environmental Protection Agency. Animal rooms were maintained on a 12:12-h photoperiod, L:D (0600:1800); food (Purina Lab Chow, Barnes Supply Co., Durham, NC) and tap water were provided ad libitum.
Beginning on GD 22, animals were checked twice daily (~8:00 AM and 5:00 PM) for births, and the date that birth was first discovered was assigned PND 0. On PND 3, litters were culled to 10 pups/litter, and 2 male and 2 female pups (randomly selected within each litter) were given foot tattoos for individual identification (Avery and Spyker, 1977) . Nontattooed pups were randomly selected from each litter for blood collection, and litter size was correspondingly reduced by 1 pup at each collection age (gender was balanced within treatment, but not analyzed due to previous data demonstrating no gender by A1254 treatment interactions; see Goldey et al., 1995a) . Animals were weaned on PND 24, and animals within a treatment group were housed in gender-matched pairs on PND 28.
Dosing
Animals were divided into two groups and exposed to corn oil alone, or a commercial PCB mixture, Aroclor 1254 (AccuStandard, Inc., Lot 6024; a congener profile (lot A4) is available in Frame et al., 1996) dissolved in corn oil, at a dose of 8 mg Aroclor 1254/kg body wt. Dams were dosed daily via oral gavage (at a volume of 1 ml/kg) from GD 6 to PND 21, except for PND 0 (the day of birth) when the dams were left undisturbed.
Thyroxine (Calbiochem; L-thyroxine, sodium salt, >99% purity) solutions were prepared daily as follows: L-thyroxine, sodium salt (Calbiochem, >99% purity) was dissolved in a 1:1 mix of ethanol and sterile saline, and the solution was subsequently diluted with saline to achieve a final diluent (vehicle) concentration of 95% saline and 5% ethanol. Beginning on PND 4, whole litters were assigned to one of four groups: corn oil plus saline (CO-S), com oil plus T4 (CO-T4), A1254 plus saline (PCB-S), or A1254 plus T4 (PCB-T4). The total of 59 litters were assigned per treatment as follows: CO-S-11; PCB-S-13; CO-T4-20; PCB-T4-15. Higher numbers in the latter two groups were necessary for additional thyroid hormone measurements on PND 7 and 21 (see below). Pups in the CO-T4 and PCB-T4 groups received individual, subcutaneous injections of T4 solution at a dose of 100 (Xg/kg body wt, whereas the CO-S and PCB-S groups received injections of vehicle. The dose of T4 selected was at the high end of doses used in previously published reports (e.g., Van Wynsberghe and Klitgaard, 1973; Deol, 1973) . All pups from each litter were injected each morning starting at 0800 h from PND 4 through PND 21, at a total volume of 10 ml/kg body wt.
Thyroid Hormone Measurements:
Circulating triiodothyronine (T3) and T4 concentrations. On PND 7, 14, and 21 (subsequent to dosing the dams with A1254 but prior to injecting pups with T4), one nontattooed pup from each of eight litters in each group was decapitated and trunk blood was collected for determination of total serum T3 and T4 concentration (see Goldey et al, 1995a, b) . At collection, whole blood by guest on November 8, 2016
http://toxsci.oxfordjournals.org/ Downloaded from samples were immediately placed on ice, allowed to clot for up to 2 h, and then centrifuged at 2500 rpm for 15 min. Serum samples were stored at -80°C until radioimmunoassay of total T3 and T4. Standard assay kits were used for determination of hormone concentrations (T3 and T4 RIA kits from Diagnostic Products, Inc.). Following completion of all behavioral testing, any remaining adult animals (approximately 1 year of age) were anesthetized with CO 2 and decapitated to collect blood for T3 and T4 analysis.
Kinetics of injected T4. On PND 7 and 21, four to five whole litters (of 10 pups each) from the CO-T4 and PCB-T4 groups were used to assess the kinetics of T3 and T4 following subcutaneous injections of T4. Total serum T3 and T4 concentrations were determined in serum samples collected from 2 pups (average value used in subsequent statistical analysis) per litter at five time points following T4 injection (1, 3, 5, 8 , and 24 h after injection, all injections at 0800 h), and all samples were collected and processed as above.
Motor Activity
One male and one female pup per litter were tested individually in one of 16 automated figure-eight mazes for 30-min sessions during the preweaning period on PND 13, 15, 17, 19, and 21 (see Ruppert et al., 1984) , and for 60-min sessions during the postweaning period on PND 29, 45, 66, 102, and 121. Motor activity was detected by eight infrared phototransistor/photodiode (photobeam) pairs. Photodetectors were sampled at a 1 -Hz rate by a microprocessor and each time a photobeam was interrupted an activity count was registered. Photobeam calibration was checked daily prior to testing. Maze assignments, order of testing, and time of day were counterbalanced across treatment groups.
Acoustic Startle Response in Preweanlings
The acoustic startle response (ASR) was assessed in one tattooed male and female pup per litter on PND 23 using the method of Ruppert et al. (1984) as modified by Crofton et al. (1989) . Testing was conducted in eight soundattenuated chambers, each containing a wire mesh, plastic-framed test cage that was mounted on a load-cell/force-transducer assembly designed to measure vertical force. Each rat was placed in a test cage and after a 10-min adaptation period at a background noise level (56 dB SPL (250-Hz high pass)), each rat received a total of 50 trials. Each trial consisted of 15 s of background white noise (70 dB SPL) followed by presentation of an eliciting stimulus (S2; 40-ms, 120 dB white noise burst with 2.5-ms rise/fall) with an intertrial interval of 15 s. Data collection began simultaneously with the presentation of the eliciting stimulus and continued for 64 ms. Response amplitudes were calculated from each animal's average response curve. For ASR testing on PND 23, amplitude was calculated as the mean response for 10 five-trial blocks.
Reflex Modification Audiometry in Adult Offspring
One male and one female rat per litter were tested for auditory thresholds and the ASR amplitude on PND 80 using the reflex modification audiometry procedure of Young and Fechter (1983) as modified by Crofton et at (1990) . Each animal was placed in one of eight test cages located in sound-isolating chambers and, following a 10-min adaptation period at an ambient noise level of 69.1 dB SPL (22.4 Hz high pass filter), each animal received a total of 240 trials. A prepulse stimulus (SI) was preceded 90 ms before the end of 10 s of ambient noise. The eliciting stimulus (S2) was presented 90 ms after the onset of SI. The trials were arranged in 10 blocks, with 24 trials per block. A block consisted of 23 trials, each trial with a different intensity of the SI stimulus (40-ms duration, 2.5-ms rise/fall, -6 to 90 dB SPL (22.4-Hz high pass filter), in 3-or 6-dB increments) presented prior to the S2 stimulus (120-dB, 40-ms burst of broadband white noise with a 2.5-ms rise/fall). Each block also contained one blank control trial, during which only S2 was presented. The order of presentation of the trials was computer generated in a semi-random but balanced fashion so that within each of ten 24-trial blocks each S1/S2 condition was presented once. The intertrial interval was 10 s, and the interstimulus interval (measured from onset of S1 to onset of S2) was 90 ms. Startle reflex amplitudes and RMA auditory thresholds were estimated using a nonlinear regression procedure (SAS, 1989) . RMA thresholds were defined as the SI intensity above which the response was inhibited and the acoustic startle amplitude was defined as the average of the 10 blank control (S2-alone) trials (see Crofton et al., 1990; Crofton, 1992, for details) . In the present study, since animals were tested at two different S1 frequencies, a mean baseline amplitude representing the average baseline amplitudes across both frequencies (for each animal) was used in statistical analyses.
Data Analysis
Analysis of variance (ANOVA) procedures were used to analyze the data (SAS, 1989) . Repeated-measures ANOVA were used to analyze body weight data for dams and offspring, age of eye opening, motor activity, and PND 23 startle habituation. Because only pups received postnatal T4 or saline injections, dams fell into one of only two groups: those which received Aroclor 1254 (PCB) or those which received corn oil (CO). For motor activity data, total counts per test session was compared across test ages using separate repeated-measured analyses for the pre-and postweaning data (due to differences in test session duration). Habituation of motor activity was not analyzed due to lack of effect of A1254 in previous work (Goldey et al., 1995a) . Auditory thresholds for 1-and 40-kHz tones were analyzed separately and the a was adjusted to 0.025 to control for Type II errors. In the case of more than one independent variable, significant interactions were followed by simpleeffects ANOVA tests for each independent variable. Where appropriate, gender was a within-litter repeated measure (to control for possible "litter effects"; see Buelke-Sam et al., 1985) , whereas treatment was a between-litter factor. All significant interactions are reported under Results section. For each significant effect of treatment, mean contrast comparisons were made using either Duncan's multiple range test or Student's t tests (SAS, 1989 ). An a value of 0.05 was used for all comparisons.
RESULTS
Maternal Body Weight
Measurements of maternal body weights throughout gestation revealed little effect of A1254 treatment (Fig. 1) . While repeated-measures analysis revealed a treatment by gestation day interaction [F(17,76) = 3.28, p < 0.0414], no main effect of treatment was found, and step-down ANOVAs at each age failed to reveal any significant differences between the two groups on any particular day (all p values > 0.07). Body weights in the treated dams never exceeded a 3.0% decrease relative to controls. During lacation, PCB-treated dams showed a moderate, but significant, body weight deficit that never exceeded 6% below controls. Repeated-measures analysis revealed a significant main effect of A1254 treatment [F{\,57) = 9.62, p < 0.003], but no treatment by day interaction. A1254 treated dams had significantly lower body weights on all postnatal days (p < 0.05). Data from nonpregnant animals and all litters used for the T4 kinetics studies were excluded from all body weight analyses.
Offspring Development
Developmental exposure to 8 mg/kg of Aroclor 1254 resulted in significant and persistent deficits in offspring body weights from birth to adulthood (Fig. 2) . During the preweaning period, deficits began at about 14% on PND 2 and increased to 35% by PND 21. Repeated-measures analysis revealed a significant treatment by age interaction [F(18,55) = 15.12,/; < 0.0001], Step-down comparisons at each day revealed significant effects of treatment at every age [all Fs(3,55) > 9.0, p > 0.0001]. Means contrast comparisons revealed differences as shown in Fig. 2 (i.e., both A1254 groups differed from the control groups but not from each other). Daily T4 treatment to PCB-T4 pups did not attenuate the body weight effects of A1254 exposure, nor did body weights differ between the CO-S and CO-T4 groups. These body weight deficits continued into adulthood. PCB-S-treated animals averaged 13 and 25% (females and males, respectively) less than CO-S animals (data not shown).
PCB-S pups demonstrated early eye opening compared to CO-S pups (Fig. 3) . In addition, age of eye opening was significantly affected by T4 therapy. The effect of T4 was to further shift eye opening toward younger ages; e.g., approximately 80% of PCB-T4 and CO-T4 pups' eyes were open on PND 14, whereas less than 5% of CO-S pups' eyes were open at this age (Fig. 3) . Repeated-measures ANOVA revealed an interaction between treatment and age of eye opening [F(12,232) = 18.36, p < 0.0001)].
Step-down ANOVAs at each age indicated significant effects of treatment on PND 13, 14, and 15 [all Fs(3,58) > 10.0, p < 0.0001]. Further, means contrast comparisons revealed the treatment-dependent differences at each age, discussed above and shown in Fig. 3 .
Thyroid Hormone Measurements
Circulating T3 and T4 concentrations. Perinatal exposure to 8 mg/kg Aroclor 1254 resulted in a reduction of circulating T4 concentrations (Fig. 4, left) . At all ages sampled (PND 7, 14, and 21), the sharp reduction in circulating T4 was apparent in the PCB-S pups and in the PCB-T4 pups (immediately prior to daily T4 injection in the latter group). These findings were supported by a significant treatment by age interaction [F(8,95) = 25.02, p < 0.0001]. ANOVAs of data collected at each age revealed that treatment-related effects were apparent on all three sampling dates [all Fs(3,36) > 23.0, p < 0.0001]. Means contrast comparisons revealed the effects detailed above and in Fig. 4 (left) .
Although total T3 concentrations were not affected in the PCB-S group at any age sampled (Fig. 4, right) , it is interesting to note that T3 concentrations in the PCB-T4 group were significantly reduced compared to both the CO-S and the PCB-S groups when measured on PND 21 (prior to daily T4 injection). These findings for T3 were supported by a significant treatment by age interaction [F(8,77) Fig. 4 (right) .
No treatment-related effects on circulating T3 or T4 concentrations were apparent when samples were collected from 1-year-old offspring (Fig. 4) . Kinetics of injected T4. Because only the CO-T4 and PCB-T4 groups were tested in the kinetics study, only these two groups were compared statistically. The results indicated that concentrations of T3 and T4 were significantly higher in the CO-T4 group than the PCB-T4 group at all time points from 1 to 24 h after T4 injection (Fig. 5) [all Fs(l,6) > 17.0; p < 0.0001]. A comparison between the time zero values at PND 7 and PND 21 and the kinetics data indicates that the T3 and T4 concentrations were dramatically elevated in the CO-T4 pups following T4 injection, and concentrations in this group remained elevated compared to CO-S (time zero) concentrations even 24 h after injection (see also Fig. 4) . On PND 7, the injection of 100 ^tg/kg T4 caused circulating concentrations of T4 (Fig. 5, top left) and T3 ( Fig. 5 ; bottom left) in the PCB-T4 group to exceed time zero CO-S concentrations during the first 8 h after injection, after which time the T3 fell back to, and T4 concentrations fell back below, the concentrations shown by time zero PCB-S animals. On PND 21, the 100 fig/kg T4 dose was less effective (than on PND 7) in bringing circulating T4 (Fig. 5 ; top right) and T3 ( Fig. 5 ; bottom right) concentrations to control (CO-S) concentrations. In the PCB-T4 group T4 concentrations never exceeded control values and were elevated to conrtol concentrations for only the first 5 to 6 h after injection. T3 concentrations in the PCB-T4 group reached only 90% of control concentrations at 3 h.
Motor Activity
Figure-eight maze testing revealed treatment dependent effects in preweaning rats (Fig. 6) . A significant reduction in activity was found in the 15-day-old PCB-S group. Daily T4 injections decreased the magnitude of this effect. The activity of the PCB-T4 pups was significantly reduced compared to the CO-S group on PND 15, but significantly increased relative to the PCB-S pups. All treated groups showed slightly lower activity on PND 17, including the CO-T4 pups. Repeated measures analysis revealed a significant age by treatment interaction [F( 12,87 
FIG. 4. Maternal
Aroclor 1254 exposure dramatically lowered total serum T4 concentration (left) at all preweaning ages, but not in 1-year-old adults. T4 replacement alone caused a large increase in total serum T4 and only partially alleviated the effects of A1254 on PND 7 (note: serum measurements conducted about 24 h after T4 injection). Total T3 was increased by T4 replacement and was significantly decreased only on PND 21 in the PCB-T4 group. CO, maternal corn-oil controls; PCB, maternal exposure to 8 mg/kg/day Aroclor 1254 from gestation day 6 through postnatal day 21; S, pup saline controls; T4, daily pup injections of 100 /ig/kg L-thyroxine from postnatal day 4 to postnatal day 21 [n = 10 litters/group at PND 7, 14, and 21; n = 5-11 litters/group at PND 365; •significantly different from the CO-S control; p < 0.05]. concentrations over a 24-h period after T4 injections to the pup on PND 7 (left) or PND 21 (right) T4 replacement injections to the pup significantly elevated both T4 and T3 on both days, with peak serum concentrations about 5 h after injection. T4 injection in the PCB-exposed pups elevated T3 and T4 concentrations above controls for most of the 24-h penod on PND 7. On PND 21, however, serum T3 and T4 concentrations rose to control concentrations (dotted lines) for less than 8 h. Note the different axes values for T3 on PND 7 and PND 21. Dashed line indicates CO-S control "time zero" concentrations for comparison. CO, maternal com-oil controls; PCB, maternal exposure to 8 mg/kg/day Aroclor 1254 from gestation day 6 through postnatal day 21; S, pup saline controls; T4, daily pup injections of 100 /xg/kg L-thyroxine from postnatal day 4 to postnatal day 21 [n = 4 litters/treatment; data are average of one male and female pup per litter, see text for statistical interpretations].
actions between treatment and gender, nor between treatment and habituation. Mean contrast comparisons revealed effects as detailed above and shown in Fig. 6 . There were no significant treatment related effects of A1254 nor T4 on motor activity at any age greater than PND 21 (data not shown).
Acoustic Startle Response
PND23 ASR. Evaluation of the acoustic startle response on PND 23 revealed that CO-T4 pups showed an elevated startle response compared to CO-S controls. In addition, both A1254 exposure groups showed reduced startle responses compared to CO-S and CO-T4 pups. T4 therapy did not "restore" the amplitude decrease caused by PCB exposure (Fig. 7) . Repeated-measures analysis revealed a main effect of treatment [F(3,28) = 21.84, p < 0.0001] and trial block (blocks of 10 trials) [F(9,20) = 6.29, p < 0.0003], but no treatment by block interaction. Therefore, only the main effect of treatment (mean of all trial blocks) is shown (Fig. 7) .
Adult ASR. Adult animals displayed a very different pattern of effects across treatment groups in that T4 replacement blocked the effects of A1254 (Fig. 7) . The PCB-S group showed significantly elevated baseline startle amplitudes compared to all other groups, whereas no significant differences were found among amplitudes of controls (CO-S and CO-T4) and the PCB-T4 group. Repeated-measures analysis revealed no effect of gender, nor any interaction with gender, on the baseline startle response. There was a significant main effect of treatment [F(3,33) = 5.33, p < 0.0042] on startle amplitude, and means contrast comparisons revealed effects described above and in Fig. 7 .
Reflex Modification Audiometry
Auditory threshold data demonstrate that daily postnatal T4 injections partially blocked the low-frequency hearing loss caused by maternal exposure to A1254. For the low frequency (1 kHz), elevated auditory thresholds were detected in both groups of animals exposed to A1254 (Fig. 8) . The 1-kHz thresholds in the PCB-S group were approximately 30 dB higher than those for control animals. The 1-kHz thresholds for the PCB-T4 were significantly higher (by 15 dB) than both control groups and significantly lower (by 15 dB) than the PCB-S group. These findings were supported by an overall effect of treatment [F(3,35) = 10.09, p < 0.0001], and means contrast comparisons revealed the treatment-dependent effects described above and shown in Fig. 8 .
At the higher frequency (40 kHz), both PCB-treated groups showed significantly elevated auditory thresholds (about 15 dB) compared to both control groups (Fig. 8 figure-eight maze) . This effect was apparent PND 15 and was partially alleviated by T4 replacement CO, maternal corn-oil controls; PCB, maternal exposure to 8 mg/kg/day Aroclor 1254 from gestation day 6 through postnatal day 21; S, pup saline controls; T4, daily pup injections of 100 /ig/kg L-thyroxine from postnatal day 4 to postnatal day 21 [n = 9-10 litters/group; "significantly different from the CO-S control; ••significantly different from the PCB-T4 group; P < 0.05].
effect of T4 was seen at this frequency. These results were supported by a significant main effect of treatment [F(3,35) = 5.51; p = 0.0033] followed by means contrast comparisons to reveal the effects shown in Fig. 8 . trations in the CO-T4 group were significantly elevated relative to all other groups. T4 concentrations in the PCB-S and PCB-T4 groups were similarly depressed relative to controls: three to four times below CO-S control concentrations prior to daily T4 injection on PND 7, 14, and 21. Only on PND 7 did T4 injections partially alleviate the PCB induced hypothyroxinemia. T3 concentrations were unchanged in the PCB-S group compared to normal (CO-S) concentrations; however, T3 concentrations in the PCB-T4 group were significantly reduced on PND 21 compared to controls (see Fig. 5, bottom right) .
Clearly, the thyroxine injections did not allow attainment of a euthyroid condition in offspring of A1254 exposed dams. When measurements were taken just prior to daily T4 injections (Fig. 4) , it appeared that T4 therapy did not appreciably alleviate the hypothyroxenemia induced by A1254 exposure. Others have demonstrated the difficulties in using T4 as a replacement therapy in xenobiotic-induced developmental hypothyroidism (see Escobar-Morreale etal, 1995 Sack et al, 1995) . The apparent inefficiency of the T4 therapy implies two possibilities: (1) that the daily T4 treatment did not significantly affect circulating hormone concentrations in PCB-T4 pups or (2) that die elevation was only temporary, and the injected T4 was cleared from the pup's body prior to die next day's dose. Our data clearly support the latter possibility and underscore die importance of knowing the kinetics of the injected hormone. T4 injections did elevate circulating T3 and T4 concentrations in both the CO-T4 and the PCB-T4 groups
DISCUSSION
In the current study, the hormonal and functional effects of developmental A1254 exposure replicated previous work, including sharply reduced circulating T4 concentrations during the early postnatal period, decreased pup body weights, early eye opening, a transient reduction in motor activity, age-dependent effects on startle response amplitudes, and low-frequency auditory threshold deficits (Goldey et al., 1995a; Herr et al., 1996) . More importantly, T4 attenuated or exacerbated some of the effects of A1254. T4 tiierapy reduced the effects of A1254 on motor activity development, startle response amplitudes in adults, and low-frequency (1 kHz) hearing loss. In contrast, T4 therapy further shifted the age of eye opening to even earlier ages than A1254 alone. Injected T4 had no measurable influence on die other endpoints measured, such as A1254-induced body weight reduction. These findings affirm that the relationship between A1254-induced toxicity and thyroid hormones is complex and that the effects of A1254 and T4 differ across the many developing systems.
Supporting previous findings (Meserve et al, 1992; Morse et al, 1993 Goldey etal, 1995a) , A1254 exposure sharply reduced circulating thyroid hormones during die preweaning period (see Fig. 4 ). As expected, daily T4 injection significantly elevated circulating thyroid hormone concentrations, but was time and treatment group dependent. T4 and T3 concen- and an increase in offspring tested as young adults. T4 injections to the pup caused an increased response at PND 23 and no effect at the adult age. T4 injections diminished the A1254-induced increase at the adult age, but had no effect on the decrease in the response seen at PND 23. CO, maternal corn-oil controls; PCB, maternal exposure to 8 mg/kg/day Aroclor 1254 from gestation day 6 through postnatal day 21; S, pup saline controls; T4, daily pup injections of 100 ng/kg t-thyroxine from postnatal day 4 to postnatal day 21 [n = 8 litters/group on PND 23; n = 8-9 litter/group for adults; *significantly different from the CO-S control; p < 0.05]. on PND 7 and PND 21, but only for a short time period during the day (see Fig. 5 ). In both groups, peak T3 and T4 concentrations were reached between 6 and 8 h after injection. The hormone concentrations in CO-T4 animals remained elevated 24 h later, whereas concentrations in the PCB-T4 group fell back to subnormal concentrations after 8 h. The transient effects of the T4 therapy are important in understanding the functional effects of T4 therapy in the PCB-treated animals (see below).
The effects of T4 replacement on PCB-induced toxicity were endpoint dependent. A1254 treatment caused significant and persistent body weight deficits in the offspring. This effect appears to be unrelated to the PCB-induced hypothyroxinemia because there was no measurable effect of T4 replacement on this endpoint. An additional possibility is that the effects on body weight are related to prenatal treatment. However, it is also possible that higher and/or more frequent T4 injections may have been more effective in ameliorating the body weight effect. Postnatal administration of either T3 or T4 has been demonstrated to block the body weight loss produced by postnatal thryoidectomy (Van Wynsberghe and Klitgaard, 1973) . While the latter explanation may be possible, it seems improbable considering that Aroclor mixtures produce a wide range of systemic effects which may contribute to body weight deficits (e.g., hepatotoxicity, wasting syndrome, porphyria; see Pohjanvirta and Tuomisto, 1994) . Thus, the ability of T4 to ameliorate all such effects seems unlikely.
Consistent with previous developmental studies of A1254 and dioxin (Madhukar ef a/., 1984; Mably et ai, 1992; Goldey et al, 1995a; Schantz et al, 1997) , we found early eye opening in the PCB-S group relative to the CO-S group. T4 treatment further shifted eye opening to earlier ages in both the CO-T4 and PCB-T4 groups (Fig. 3) . Acceleration of eye opening has been reported following postnatal T4 injections (Shapiro, 1968; Van Wynsberghe and Klitgaard, 1973; Brunjes and Alberts, 1981; Freeman and Sohmer, 1995) and may involve activation of EGF receptors (Lakshmanan et al, 1985; Aim et al, 1988) . In contrast, developmental hypothyroidism results in delays in eye opening (Comer and Norton, 1982; Adams et al, 1989; Savage et al, 1990; Goldey et al, 1995b) . Of methodological importance, these results gave the earliest indication that the injected hormone had biological activity in vivo, but it was of greater interest to note that PCB treatment had an effect similar to T4 injections rather than hypothyroidism. The effect of A1254 on eye opening cannot be related simply to lowered circulating T4 concentrations, since we would have expected delayed eye opening. It is possible that due to their structural similarities to thyroid hormones (McKinney and Waller, 1994) , PCBs (and/or metabolites) may actually bind to thyroid hormone receptors in tissues responsible for controlling age of eye opening and thus mimic endogenous or injected thyroid hormones. No data exist to support or refute this hypothesis. An alternative explanation is that A1254 contains congeners that activate the Ah receptor. The early eye opening following developmental TCDD exposure (Madhukar et al, 1984; Schantz et al, 1997) has been postulated to result from Ah receptor activation by TCDD and subsequent atterations in EGF signaling pathways (Madhukar et al, 1988) . Activation of EGF receptors during development is well known to induce early eye opening (Cohen, 1962; Schlessinger et al, 1983; Lakshmanan et al, 1985; Aulerich et al, 1988) . This hypothesis suggests that A1254 may affect eye opening through a mechanism completely unrelated to thyroid hormones; however, it remains to be tested.
T4 replacement therapy reduced the effects of A1254 on the ontogeny of motor activity. Consistent with a previous report (Goldey et al, 1995a ) A1254 reduced activity on PND 15 in the PCB-S group relative to the controls (Fig. 6 ). T4 therapy blocked 60% of this effect. The activity counts of the PCB-T4 group at this age were significantly elevated over the PCB-S group, although PCB-T4 counts were still below the CO-S controls. This finding provides evidence that thyroid hormones are important in the normal development of pathways involved in the performance of this task and that the reduced concentrations of these hormones caused by A1254 exposure were responsible, at least in part, for the developmental delay in this activity. This effect on motor activity development would be easy to miss in a toxicological investigation due to its transient nature. In addition, evaluating endpoints in which damage is likely to be permanent (such as effects on auditory structures), regardless of when the insult occurs, will be less likely to yield false-negative results.
The evaluation of the acoustic startle response revealed an age-dependent effect of T4 replacement. A1254 exposure decreased the ASR at the early age, an effect reported in our previous study (Goldey etai, 1995a) . However, this effect was not alleviated by T4 replacement. Similarly, Gottesfeld and Silverman (1990) reported the inability of T3 to block the delayed maturation of the ASR following alcohol-induced hypothyroidism. While this effect may be related to a delay in ASR pathway maturation caused by sharply reduced concentrations of circulating T4, as occurs during hypothyroidism (Comer and Norton, 1982; Golden, 1986, 1987) , this finding may be confounded by the reduced body weights in the PCB-exposed groups. However, when these same animals were tested for ASR amplitudes as adults, neonatal T4 injections normalized the effects of A1254. Interestingly, A1254-treated animals showed significantly elevated response amplitudes compared to the other treatment groups (Fig. 7) , despite the persistently lower body weights. It should be noted that while we did not find elevated ASR amplitudes in adult animals similarly exposed to A1254 in our previous study (Goldey et ai, 1995a) , we did find this effect in adult animals following goitrogen-induced perinatal hypothyroidism (Goldey et ai, 1995b) .
Testing at the early age (PND 23) also showed that T4 injections alone caused elevated ASR amplitudes compared to saline-injected controls (Fig. 7) . Thus, T4 enhances the amplitude, or the maturation, of the response in control animals. This is consistent with previous findings that hyperthyroidism leads to early onset of anatomical, behavioral and physiological markers of the auditory system (Brunjes and Alberts, 1981; Sohmer and Freeman, 1995; Freeman and Sohmer, 1995; Freeman et al., 1996) , as well as accelerated development of the startle response (Shapiro, 1968; Golden, 1986, 1987) .
The present study provides evidence that postnatal T4 replacement attenuates the low-frequency hearing loss induced by perinatal maternal A1254 exposure. This finding suggests that the low-frequency hearing loss previously reported (Goldey et ai, 1995a; Herr et al., 1996) was caused, at least in part, by the A1254-induced reduction in thyroid hormones (Meserve et al., 1992; Goldey et al, 1995a; Morse et al., 1993 Morse et al., , 1996 . At the high frequency, A1254-treated animals showed a more moderate increase in auditory thresholds (a visible trend in our previous study which was not statistically significant; Goldey et al., 1995a) ; however, this effect was not attenuated by T4 treatment. The developmental progression of the auditory system may contribute to the frequency-dependent nature of the present findings.
In the rat, thyroid hormones must be present during the first few postnatal weeks for proper development of cochlear structures (Uziel, 1986) . Hypothyroidism during this period results in permanent malformation of cochlear structures and functional hearing loss, and T4 replacement therapy during the postnatal period allows for more normal functional and anatomical development (Deol, 1973 (Deol, , 1976 Uziel et ai, 1980 Uziel et ai, , 1981 Uziel et ai, , 1985a Meza et ai, 1996) . Cochlear development is tonotopic (Miiller, 1991a,b) in that basal regions (which develop early) are sensitive to higher frequencies (e.g., 40 kHz) and apical regions (which mature later) are sensitive to lower frequencies (e.g., 1 kHz) (for review, see Rubel, 1978 Rubel, , 1985 . Thus, based on the finding that T4 replacement significantly attenuated the low-frequency hearing loss in A1254-treated animals, it is reasonable to conclude that the T4 replacement stimulated apical structures of the cochlea to develop in A1254-T4 animals, even though normal development was not achieved. This reasoning, however, does not explain the lack of effect of T4 replacement on the high-frequency hearing loss induced by A1254. This inadequacy of T4 replacement may be due to a number of factors. First, the therapy did not start until PND 4 and the basal structures receptive to 40-kHz tones may have passed a "critical window." The cochlear-sensitive period for hypothyroidism in rats varies from GD 19 to PND 15, depending upon the anatomical structure (Deol, 1973; Hebert etai, 1985; Uziel et ai, 1985a,b) and lack of knowledge of the exact cochlear structures affected by A1254 exposure hampers any conclusions on this point. Second, multiple sites within the cochlea may be affected by the A1254-induced hypothyroidism. Therefore, T4 replacement from PND 4 to PND 21 may have alleviated the damage to one site partially responsible for the low-frequency effect and had no effect on the site of damage responsible for the high frequency effect. Third, the dose of T4 used did not allow attainment of a euthyroid condition in the A1254 pups. It is possible that multiple daily doses or combined maternal and pup doses throughout gestation and lactation may be more efficacious. Finally, one cannot, at this time, rule out the possibility that PCBs may cause some direct damage to auditory structures independent of thyroid signaling.
In summary, the present findings demonstrate the reproducibility of the effects of A1254 on a number of functional and systemic endpoints and strengthen the hypothesis that some of the effects on auditory, startle, and motor function are caused by the PCB-induced hypothyroxinemia. Based on the differences in the timing of auditory development in rats and humans, it is reasonable to predict that humans exposed in utero to thyrotoxic compounds may be more likely to show auditory deficits than if exposure occurs sometime after birth. While a number of epidemiological studies of children prenatally exposed to PCBs and similar compounds indicate that neurological endpoints are affected by these compounds (e.g., Huisman et ai, 1995; Chen and Hsu, 1994; Jacobson et ai, 1990; Rogan et ai, 1986) , to date none have included an assessment of their subjects' auditory function. The current findings suggest the importance of incorporating sensitive audiometric assessments in to studies of at-risk populations.
